ITT1 Antibody

What is the ITT1 antibody and what does it detect?

The ITT1501 antibody (sometimes referred to as ITT1 antibody) is a polyclonal antibody that specifically detects endogenous levels of HAND1 protein . HAND1 (Heart- and neural crest derivatives-expressed protein 1) belongs to the basic helix-loop-helix family of transcription factors that play essential roles in cardiac morphogenesis and development . This antibody has been developed through affinity purification of rabbit antiserum using epitope-specific immunogen derived from the HAND1 protein .

What is the specificity profile of the ITT1 antibody?

The ITT1 antibody is designed to detect endogenous levels of HAND1 protein with high specificity . It recognizes the HAND1 protein in human, mouse, and rat samples . The antibody was developed using a synthesized peptide derived from HAND1 at amino acid range 40-120, which serves as the specific immunogen . Affinity purification using epitope-specific immunogen ensures high specificity for the target protein, minimizing cross-reactivity with other proteins .

How does ITT1 antibody relate to Itt1p protein research?

While the commercial ITT1501 antibody targets HAND1 protein, researchers should be aware of potential confusion with Itt1p, which is an entirely different protein. Itt1p is a novel protein identified in Saccharomyces cerevisiae that functions as an inhibitor of translation termination . Research has demonstrated that Itt1p enhances the readthrough of UAA, UAG, and UGA nonsense codons when overexpressed, and interacts with translation termination factors . Antibodies against Itt1p would be different research tools than the commercial ITT1501 antibody for HAND1 detection.

What are the validated applications for ITT1 antibody in experimental protocols?

The ITT1501 antibody has been validated for immunohistochemistry on paraffin-embedded tissues (IHC-p) and enzyme-linked immunosorbent assay (ELISA) . For immunohistochemistry applications, the recommended dilution range is 1:100 to 1:300, which should be optimized based on specific experimental conditions and tissue samples . For ELISA applications, a much higher dilution of 1:20000 is recommended . While these applications have been validated, researchers should conduct preliminary experiments to determine optimal conditions for their specific experimental systems.

How should researchers design control experiments when using ITT1 antibody?

When designing experiments with ITT1 antibody, researchers should include appropriate controls:

• Positive control: Tissues or cells known to express HAND1 (cardiac tissues, particularly developing ventricles)

• Negative control: Tissues not expressing HAND1

• Antibody controls:

  • Primary antibody omission

  • Isotype control (non-specific IgG from the same host species)

  • Blocking peptide competition assay using the immunizing peptide (amino acids 40-120 of HAND1)

• Method controls: Standard curve validation for ELISA applications

These controls help validate specificity and eliminate false positive or negative results that might arise from non-specific binding or procedural errors.

What methodological approaches can overcome potential cross-reactivity issues?

To address potential cross-reactivity issues when using ITT1 antibody, researchers should consider:

• Pre-absorption with the immunizing peptide to confirm specificity

• Western blot analysis to verify single-band detection at the expected molecular weight

• Comparative analysis with alternative HAND1 antibodies targeting different epitopes

• Genetic validation through HAND1 knockdown/knockout samples

• Dual labeling with alternative HAND1 detection methods to confirm co-localization

These approaches help distinguish between specific signal and potential cross-reactivity with structurally similar proteins, particularly other basic helix-loop-helix family members.

How can ITT1 antibody be incorporated into studies of cardiac development?

For cardiac development studies, ITT1 antibody can be strategically employed to:

• Track temporal and spatial expression patterns of HAND1 across developmental stages

• Identify cardiac progenitor cells expressing HAND1 through immunohistochemistry

• Correlate HAND1 expression with cardiac morphological changes

• Analyze the effects of genetic manipulations on HAND1 expression

• Study protein-protein interactions through co-immunoprecipitation with other cardiac developmental factors

Researchers should employ stage-specific embryonic tissues and compare HAND1 expression with other cardiac markers to establish developmental relationships. The antibody's specificity for HAND1 makes it valuable for distinguishing between HAND1 and HAND2 expression domains, which have distinct roles in cardiac chamber formation.

What are the technical considerations for using ITT1 antibody in multiplex immunofluorescence studies?

For multiplex immunofluorescence studies, researchers should consider:

• Antibody compatibility: Ensure primary antibodies are from different host species to avoid cross-reactivity with secondary antibodies

• Epitope retrieval optimization: HAND1 detection may require specific antigen retrieval methods that must be compatible with other target proteins

• Signal amplification systems: For low-abundance targets, tyramide signal amplification or similar methods may be necessary

• Fluorophore selection: Choose fluorophores with minimal spectral overlap and appropriate brightness for the relative abundance of each target

• Sequential staining protocols: When using multiple rabbit antibodies, consider sequential staining with complete stripping between rounds

These considerations help ensure accurate co-localization studies when examining HAND1 in relation to other developmental factors or cellular markers.

How can researchers integrate ITT1 antibody into ChIP-seq experiments to study HAND1 transcriptional targets?

For chromatin immunoprecipitation sequencing (ChIP-seq) applications:

• Optimize crosslinking conditions specifically for HAND1, typically starting with 1% formaldehyde for 10 minutes

• Validate antibody efficacy through ChIP-qPCR on known HAND1 binding regions before proceeding to sequencing

• Use a dual crosslinking approach (DSG followed by formaldehyde) to improve capture of indirect DNA interactions

• Implement stringent washing conditions to reduce background

• Compare results with published HAND1 binding motifs to validate specificity

Although ITT1501 hasn't been specifically validated for ChIP applications in the provided information, polyclonal antibodies against transcription factors can often be adapted for ChIP with proper optimization and validation.

How can ITT1 antibody contribute to congenital heart disease research?

The ITT1 antibody can be valuable in congenital heart disease research through:

• Immunohistochemical analysis of HAND1 expression patterns in normal versus malformed cardiac tissues

• Correlation of HAND1 expression levels with specific cardiac malformations

• Identification of altered HAND1 regulatory pathways in disease models

• Examination of HAND1 protein interactions in pathological states

• Validation of genetic variants affecting HAND1 expression or function

Since HAND proteins play essential roles in cardiac morphogenesis and are implicated as mediators of congenital heart disease , the ITT1 antibody provides a tool to examine protein-level alterations that may not be evident from genetic or transcriptomic analyses alone.

What insights can ITT1 antibody provide in cancer research related to HAND1?

In cancer research applications, the ITT1 antibody can help:

• Evaluate HAND1 expression across tumor types, particularly breast cancer where HAND1 alterations have been reported

• Assess HAND1 as a potential biomarker by correlating expression with clinical outcomes

• Investigate the relationship between HAND1 and cellular differentiation state in tumors

• Examine epigenetic regulation of HAND1 in cancer progression

• Study HAND1's potential role in tumor cell migration and invasion

While exploring these applications, researchers should be aware that antibody-based approaches provide protein-level information that complements genomic and transcriptomic analyses, potentially revealing post-translational modifications and protein stability differences relevant to cancer biology.

What are common technical challenges when using ITT1 antibody and how can they be addressed?

Common challenges and solutions include:

How should researchers interpret conflicting results between ITT1 antibody detection and other HAND1 detection methods?

When facing discrepancies between ITT1 antibody results and other HAND1 detection methods:

• Consider epitope accessibility differences between methods (the ITT1501 antibody targets amino acids 40-120 of HAND1)

• Evaluate post-translational modifications that might affect antibody recognition but not mRNA detection

• Assess protein stability and turnover rates that could create differences between protein and mRNA levels

• Examine potential splice variants that might be differentially detected

• Validate with alternative antibodies targeting different HAND1 epitopes

Discrepancies often provide valuable insights into regulatory mechanisms rather than indicating experimental failure, and should be documented and investigated thoroughly.

What storage and handling practices maximize ITT1 antibody performance and longevity?

To maintain optimal antibody performance:

• Store at -20°C as recommended for long-term stability (up to 1 year)

• Prepare small working aliquots to minimize freeze-thaw cycles

• When in use, keep on ice and return to -20°C promptly

• The antibody is supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability

• Monitor performance over time with consistent positive controls

• Follow manufacturer's concentration specifications (1 mg/ml as supplied)

Proper handling practices significantly impact experimental reproducibility and extend the functional lifespan of the antibody.

How might ITT1 antibody applications expand with emerging single-cell technologies?

The integration of ITT1 antibody with emerging single-cell technologies presents exciting research opportunities:

• Single-cell Western blotting to quantify HAND1 protein levels in individual cells

• Mass cytometry (CyTOF) incorporation for high-dimensional analysis of HAND1 alongside dozens of other proteins

• Spatial transcriptomics combined with HAND1 immunostaining to correlate protein expression with transcriptional profiles

• Microfluidic antibody capture for quantitative single-cell protein analysis

• In situ sequencing with protein detection to link genetic variations with HAND1 expression

These approaches could reveal previously unrecognized heterogeneity in HAND1 expression within apparently homogeneous cell populations and tissues.

What comparative insights might be gained by studying Itt1p versus HAND1 using specific antibodies?

Although Itt1p (the yeast protein) and HAND1 (the transcription factor detected by ITT1501) are entirely different proteins, comparative studies using specific antibodies against each could provide insights into:

• Evolutionary conservation of protein regulation mechanisms

• Structural analysis of protein domains with similar functions despite sequence divergence

• Convergent evolution of protein-protein interaction networks

• Translation regulation effects on developmental transcription factors

• Regulatory principles common to both translation termination and transcriptional control

Itt1p has been shown to inhibit translation termination in yeast, interacting with eRF1 and eRF3 release factors . Understanding these regulatory mechanisms might provide unexpected parallels to transcription factor regulation.